Dr Denis Lacombe is involved in the coordination and administration of all EORTC activities to promote EORTC as a major European organisation in cancer clinical and translational research. He is responsible for scientific and public policy activities, developing and implementing medium-term strategies as defined by the EORTC Board, and internal and external communications.
Scientist: Denis Lacombe
A scientist’s opinion : Interview with Dr Denis Lacombe about re-engineering pharmaceutical research
Interview with Dr Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer (EORTC) about Re-engineering pharmaceutical research. Can you tell me a bit about the European Organisation for Research and Treatment of Cancer (EORTC)? Denis Lacombe: We are a non-governmental, not-for-profit organisation established for 60 years, focusing on survival and ...
Re-engineering pharmaceutical research for better patient outcomes
A so-called ‘productivity crisis’ has been ascribed to the pharmaceutical research and development industry. Despite increases in investment and funding, this has not corresponded to increases in the approval of novel drugs. Why do so many drugs fail to receive approval, and what other means should we be focusing on for the benefit of patients?